Vivimed Labs consolidated revenue for the quarter came in at Rs. 437 crore, registering 25.9% yoy increase. This was mainly driven by 127% yoy increase in Speciality Chemicals Business.
EBITDA for the quarter rose by 287.5% yoy to Rs. 186 crore with a corresponding margin expansion of 2873 bps. EBITDA margin for the quarter stood at 42.6%. This margin expansion was aided by 23% yoy decrease in cost of material consumed.
The PAT for the quarter came in at Rs. 115 crore, yoy increase of 784.6%. This was due to jump in revenue and also supported by 26% yoy decline in finance cost.
Looking at the full year numbers, we see that revenue jumped by 9% to reach Rs.1461.91 crore while EBITDA rose by 77% to 411.7 crore. Company reported net profit of Rs.221.74 crore, up 165% yoy.
The board has recommended dividend of Rs. 0.40 per share for the face value of Rs. 2 each.
Vivimed Labs Ltd is currently trading at Rs. 118.45, up by 7.4 points or 6.66% from its previous closing of Rs. 111.05 on the BSE.
The scrip opened at Rs. 127.9 and has touched a high and low of Rs. 127.9 and Rs. 117.3 respectively. So far 1507856(NSE+BSE) shares were traded on the counter. The stock is currently trading below its 50 DMA.
Latest posts by Ruby Khatun (see all)
- JnJ faulty hip implants case: CIC directs RTI disclosure of records - September 10, 2018
- Max Bupa launches WeCare initiative to aid Kerala flood victims - September 10, 2018
- Opposing Online Pharmacies, 8.5 lakh chemists to call it a strike on September 28 - September 9, 2018